Vitamin D Deficiency Repletion Guidelines

Classification & Target Levels

• A serum 25‑hydroxyvitamin D concentration of 19.6 ng/mL is classified as vitamin D deficiency ( < 20 ng/mL) and warrants active repletion to achieve a target ≥ 30 ng/mL. (American Association of Clinical Endocrinologists/American College of Endocrinology) 1
• The same societies define sufficiency as ≥ 30 ng/mL because secondary hyperparathyroidism becomes increasingly common below this threshold. (AACE/ACE) 2

Repletion Regimens

Daily High‑Dose Regimen (Preferred)

• Prescribe 5,000 IU vitamin D₃ daily for 8–12 weeks to raise serum 25(OH)D above 30 ng/mL. (Endocrine Society guideline) 1
• Daily dosing mimics physiologic cutaneous production and avoids metabolic complications associated with large bolus dosing. (Endocrine Society) 2
• It prevents 24‑hydroxylation that converts vitamin D to inactive metabolites, thereby preserving efficacy. (Endocrine Society) 1

Weekly High‑Dose Regimen (Alternative)

• Prescribe 50,000 IU vitamin D₃ (or D₂) once weekly for 8 weeks (total 400,000 IU). (Journal of the National Comprehensive Cancer Network) 3
• This regimen effectively corrects deficiency in most adults and is endorsed by the Endocrine Society guidelines. (Endocrine Society) 4
• Weekly dosing may improve adherence for patients preferring less frequent administration. (Autoimmunity Reviews) 5

Formulation Preference

• Vitamin D₃ (cholecalciferol) is strongly preferred over vitamin D₂ (ergocalciferol) because it sustains serum 25(OH)D concentrations longer and yields greater increases, especially with intermittent dosing. (Endocrine Society) 1
• Many 25(OH)D assays have limited cross‑reactivity with 25(OH)D₂, potentially producing spuriously low total values when vitamin D₂ is used. (Endocrine Society) 2
• For patients (e.g., vegetarians) who decline vitamin D₃, vitamin D₂ can be used with daily dosing, but LC‑MS/MS assays should be employed to accurately quantify both forms. (Endocrine Society) 1

Dose Adjustment When Target Not Met

• If serum 25(OH)D remains < 30 ng/mL despite adherence, increase the maintenance dose to 3,000–6,000 IU daily. (Endocrine Society & clinical endocrinology literature) 4
• Evaluate for malabsorption syndromes (celiac disease, inflammatory bowel disease, cystic fibrosis) as potential causes of inadequate response. (Endocrine Society) 4
• Assess for obesity (BMI > 30), which sequesters vitamin D in adipose tissue and often requires 2–3 × the standard dose. (Endocrine Society) 4

Maintenance Therapy

• After achieving ≥ 30 ng/mL, prescribe 1,000–2,000 IU vitamin D₃ daily for long‑term maintenance. (Endocrine Society) 1
• Higher maintenance doses (3,000–6,000 IU daily) may be necessary in obesity, malabsorption, or when patients are on medications that accelerate vitamin D metabolism (e.g., anticonvulsants, glucocorticoids, rifampin). (Endocrine Society & clinical endocrinology literature) 4
• Rule of thumb: each additional 1,000 IU/day raises serum 25(OH)D by ≈ 10 ng/mL, though individual responses vary. (Autoimmunity Reviews) 5

Safety Considerations

• Avoid large annual bolus doses (e.g., 500,000 IU); randomized trials have shown increased falls and fractures in older adults receiving such regimens. (Endocrine Society) 1
• Monthly boluses ≥ 60,000 IU are also linked to higher fall risk in frail elderly patients with baseline levels similar to the case described. (Endocrine Society) 2
• In granulomatous diseases (sarcoidosis, tuberculosis, chronic fungal infections) or lymphoma, repletion must be cautious due to the risk of hypercalcemia from unregulated extrarenal 1,25(OH)₂D production; monitor serum calcium. (Endocrine Society & clinical endocrinology literature) 4
• In primary hyperparathyroidism with concurrent deficiency, repletion is still recommended, but calcium should be monitored; most patients do not develop worsening hypercalcemia. (Clinical endocrinology literature) 4

Calcium Co‑supplementation

• Ensure adequate calcium intake (1,000–1,200 mg/day) from diet and supplements to optimize bone health and vitamin D efficacy. (Endocrine Society) 1

High‑Risk Groups & Dose Modifications

All recommendations are based on guideline statements and peer‑reviewed evidence from the American Association of Clinical Endocrinologists, American College of Endocrinology, Endocrine Society, and related clinical research.

Vitamin D Insufficiency Management Guidelines

Classification & Target Levels

• Serum 25‑hydroxyvitamin D of 29.5 ng/mL falls just below the sufficiency threshold of ≥30 ng/mL recommended by the American Association of Clinical Endocrinologists and the Endocrine Society; levels below this cutoff are associated with increasing secondary hyperparathyroidism. 6
• A concentration of 20–29 ng/mL is defined as vitamin D insufficiency, which warrants active repletion rather than simple maintenance dosing. 7

Repletion Regimens

Preferred Daily High‑Dose Approach

• Prescribe 5,000 IU vitamin D₃ (cholecalciferol) daily for 8–12 weeks to raise serum 25‑hydroxyvitamin D above 30 ng/mL; this regimen is endorsed by the American Association of Clinical Endocrinologists and the Endocrine Society. 7
• Daily dosing mimics physiologic cutaneous synthesis and avoids metabolic complications of large bolus doses (e.g., excess 24‑hydroxylation to inactive metabolites). 6
• In older adults, daily dosing prevents the increased fall risk observed with monthly or annual bolus regimens. 6

Alternative Weekly High‑Dose Regimen

• An alternative is 50,000 IU vitamin D₃ once weekly for 8 weeks (total 400,000 IU), which effectively corrects insufficiency in most adults and is endorsed by the Endocrine Society. 8

Maintenance Therapy

• After achieving a serum level ≥30 ng/mL at 8–12 weeks, transition to 1,500–2,000 IU vitamin D₃ daily for long‑term maintenance; this dose reliably sustains levels above 30 ng/mL in standard‑risk adults. 8
• If the target is not reached despite documented adherence, increase the maintenance dose to 3,000–6,000 IU daily and evaluate for underlying malabsorption syndromes (e.g., celiac disease, inflammatory bowel disease, cystic fibrosis). 8

Dose Adjustments for High‑Risk Populations

Obesity (BMI ≥30 kg/m²)

• Obese patients require 2–3 × the standard dose because vitamin D is sequestered in adipose tissue; a maintenance dose of 3,000–6,000 IU daily is recommended to sustain target levels. 8

Malabsorption Syndromes

• Conditions such as celiac disease, Crohn’s disease, cystic fibrosis, or post‑bariatric surgery require 6,000–10,000 IU vitamin D₃ daily to achieve target serum concentrations. 8

Enzyme‑Inducing Medications

• Patients on anticonvulsants (phenytoin, carbamazepine), glucocorticoids, or rifampin need 4,000–6,000 IU vitamin D₃ daily to offset increased vitamin D metabolism. 8

Safety Considerations

• Daily doses up to 4,000 IU are considered absolutely safe without medical supervision; therapeutic doses up to 10,000 IU daily may be required in high‑risk patients when monitored appropriately. 8
• Large annual bolus doses (e.g., 500,000 IU) are associated with increased falls and fractures in older adults and should be avoided. 6
• Monthly bolus doses ≥60,000 IU are linked to higher fall risk in frail elderly patients and are not recommended. 6

Special Clinical Situations

• In granulomatous diseases (sarcoidosis, tuberculosis, chronic fungal infections), repletion must be cautious because unregulated extrarenal 1,25‑dihydroxyvitamin D production can cause hypercalcemia; a lower target range of 20–30 ng/mL with concurrent calcium monitoring is advised. 8
• For patients with primary hyperparathyroidism, vitamin D repletion is still recommended; serial calcium monitoring is required throughout therapy to detect any worsening hypercalcemia. 8

Assay Considerations

• Many 25‑hydroxyvitamin D assays have limited cross‑reactivity with 25‑hydroxyvitamin D₂, potentially yielding spuriously low total values when vitamin D₂ is used; therefore, vitamin D₃ is preferred. 6
• When vitamin D₂ is chosen (e.g., for vegetarians), liquid chromatography–tandem mass spectrometry (LC‑MS/MS) assays should be employed to accurately quantify both D₂ and D₃ forms. 6